Patrick R. O’neil Sells 1,000 Shares of Ionis Pharmaceuticals Inc. (IONS) Stock
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $45.00, for a total value of $45,000.00. Following the transaction, the senior vice president now directly owns 9,720 shares in the company, valued at approximately $437,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 48.16 on Wednesday. The stock’s 50 day moving average price is $32.49 and its 200 day moving average price is $30.24. Ionis Pharmaceuticals Inc. has a one year low of $19.59 and a one year high of $63.71. The stock’s market cap is $5.84 billion.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 9th. The company reported $0.06 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by $0.02. The firm had revenue of $110.90 million for the quarter, compared to analysts’ expectations of $114.65 million. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The firm’s revenue was up 125.9% on a year-over-year basis. Analysts forecast that Ionis Pharmaceuticals Inc. will post ($1.11) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company bought a new stake in Ionis Pharmaceuticals during the third quarter valued at $126,000. Rockefeller Financial Services Inc. bought a new stake in Ionis Pharmaceuticals during the second quarter valued at $114,000. HL Financial Services LLC bought a new stake in Ionis Pharmaceuticals during the third quarter valued at $216,000. US Bancorp DE increased its stake in Ionis Pharmaceuticals by 37.8% in the second quarter. US Bancorp DE now owns 5,952 shares of the company’s stock valued at $139,000 after buying an additional 1,634 shares during the period. Finally, Prudential Financial Inc. bought a new stake in Ionis Pharmaceuticals during the third quarter valued at $232,000. Hedge funds and other institutional investors own 88.35% of the company’s stock.
A number of research firms have recently commented on IONS. Vetr cut Ionis Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $38.22 target price on the stock. in a research note on Tuesday. BMO Capital Markets upped their target price on Ionis Pharmaceuticals from $25.00 to $40.00 and gave the company a “market perform” rating in a research note on Monday, August 1st. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, November 9th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $35.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, November 10th. Finally, Jefferies Group reaffirmed a “sell” rating and set a $17.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, November 10th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $41.85.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.